EIOC Shares Results from IMforte Trial in Small Cell Lung Cancer
Excellence in Oncology Care – EIOC shared a post on X :
“Results of IMforte trial of:
Lurbinectedin + Atezolizumab as 1st line Maintenance Tx in Extensive stage Small Cell Lung Cancer.
Significant improvement in pfs hr 0.54.
Significant improvement in os hr 0.73.”
On which Alex Friedlaender, Chief resident at the Geneva University Hospitals, commented:
“The no crossover allowed part is probably limiting in a lot of countries where options are very limited… I wonder what would happen with the 3m most benefit with crossover.”
Alfredo Addeo, Chief resident at the Geneva University Hospitals, also shared his view on this:
“Tbh I don’t buy it, lurbi has yet to prove OS benefit in 2nd line.
The main limitation of the study is not allowing pts with brain mts in the study.
This is a very selected trial with very selected pts hence no widely adoptable in clinic but limited to some pts.”
More posts featuring Excellence in Oncology Care.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023